Aldosterone induces mesangial cell apoptosis both in vivo and in vitro

American Journal of Physiology - Renal Physiology

Volumn 295, Issue 1, 2008, Pages

  Mathew, Jayant T ^a   Patni, Hitesh ^a   Chaudhary, Ahmad N ^a   Liang, Wei ^b   Gupta, Aakriti ^a   Chander, Praveen N ^c   Ding, Guohua ^b   Singhal, Pravin C ^a,d  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d Div of Kidney Diseases and Hypertension   (United States)

Author keywords

Aldosterone; Apoptosis; Mesangial cells

Indexed keywords

ALDOSTERONE; ANTIOXIDANT; CYTOCHROME C; EPLERENONE; SCAVENGER; SPIRONOLACTONE; ALDOSTERONE ANTAGONIST; BAD PROTEIN, HUMAN; CREATININE; CYCLINE; DRUG DERIVATIVE; PROTEIN BAD;

ALBUMINURIA; ANTIBODY LABELING; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DEPHOSPHORYLATION; GLOMERULUS; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FAILURE; MALE; MESANGIUM CELL; MITOGENESIS; MOLECULAR MECHANICS; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; BLOOD; BLOOD PRESSURE; CYTOLOGY; DRUG EFFECT; METABOLISM; OXIDATIVE STRESS; SPRAGUE DAWLEY RAT;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; ANTIOXIDANTS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BLOOD PRESSURE; CREATININE; CYTOCHROMES C; FREE RADICAL SCAVENGERS; HUMANS; IN SITU NICK-END LABELING; KIDNEY GLOMERULUS; MALE; MESANGIAL CELLS; OXIDATIVE STRESS; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; SPIRONOLACTONE;

EID: 49949102889     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00435.2007     Document Type: Article

References (52)

1. Aizawa T, Ishizaka N, Kurokawa K, Nagai R, Nakajima H, Taguchi J, Ohno M. Different effects of angiotensin II and catecholamine on renal cell apoptosis and proliferation in rats. Kidney Int 59: 645-653, 2001.
2. Arends MJ, Harrison DJ. Novel histopathological findings in a surviving case of hemolytic uremic syndrome after bone marrow transplantation. Hum Pathol 20: 89-91, 1989.
3. Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, Savill J. Mesangial cell apoptosis: the major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J Clin Invest 94: 2105-2116, 1994.
4. Ben Rhouma K, Schimchowitsch S, Stoeckel ME, Felix JM, Sakly M. Implication of type II glucocorticoid receptors in aldosterone induced apoptosis of rat thymocytes. Arch Physiol Biochem 105: 216-224, 1997.
5. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63: 1791-1800, 2003.
6. Border WA, Noble NA. Interaction of transforming growth factor-β and angiotensin I.I. in renal fibrosis. Hypertension 31: 181-188, 1998.
7. Campbell SE, Janicki JS, Matsubara BB, Weber KT. Myocardial fibrosis in the rat with mineralocorticoid excess. Am J Hypertens 6: 487-495, 1993.
8. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, Welch WJ, Wilcox CS. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39: 269-274, 2002.
9. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345: 925-926, 2001.
10. De Angelis N, Fiordaliso F, Latini R, Calvillo L, Funicello M, Gobbi M, Mennini T, Masson S. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol 34: 1655-1665, 2002.
11. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 49: 578-598, 1996.
12. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 19: 829-842, 2001.
13. Floege J, Burns MW, Alpers CF, Yoshimura A, Pritzel P, Gordon K, Seifert R, Brown-Pope DF, Couser WG, Johnson RJ. Glomerular cell proliferation, and matrix synthesis. Kidney Int 41:297-309, 1992.
14. Fogo AB. Progression and potential regression of glomerulosclerosis. Kidney Int 59: 804-819, 2001.
15. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98: 1063-1068, 1996.
16. Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, Kim HK, Kim YS, Cha DR. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 70: 111-120, 2006.
17. Harrison DJ. Cell death in the diseased glomerulus. Histopathology 12: 679-683, 1998.
18. Hattori T, Shindo S, Kawamura H. Apoptosis and expression of Bax protein and Fas antigen in glomeruli of a remnant-kidney model. Nephron 79: 186-191, 1998.
19. Inoue CN, Nagano I, Ichinohasama R, Asato N, Kondo Y, Iinuma K. Bimodal effects of platelet-derived growth factor on rat mesangial cell proliferation and death and the role of lysophosphatidic acid in cell survival. Clin Sci (Colch) 101: 11-19, 2001.
20. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 318: 1657-1666, 1988.
21. Mano A, Tatsumi T, Shiraishi J, Keira N, Nomura T, Takeda M, Nishikawa S, Yamanaka S, Matoba S, Kobara M, Tanaka H, Shirayama T. Aldosterone directly induces myocyte apoptosis through calcineurin dependent pathways. Circulation 110: 317-323, 2004.
22. Martinez-Salgado C, Eleno N, Morales AI, Perez-Barriocanal F, Arevalo M, Lopez-Novda JM. Gentamicin treatment induces simultaneous mesangial proliferation and apoptosis in rats. Kidney Int 65: 2167-2171, 2004.
23. Meng S, Cason GW, Gannon AW, Racusen LC, Manning RD Jr. Oxidative stress in Dahl salt-sensitive hypertension. Hypertension 41: 1346-1352, 2003.
24. Michael AF, Keane WF, Raij L, Vernier RL, Mauer SM. The glomerular mesangium. Kidney Int 17: 141-154, 1980.
25. Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP, Kimura S, Yukimura T, Kiyomoto H, Kohno M, Abe Y, Nishiyama A. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16: 2906-2912, 2005.
26. Nishikawa T, Suematsu S, Saito J, Ito H, Kino T, Chrousos G. Human mesangial cells produce aldosterone in response to low density lipoprotein (LDL). J Steroid Biochem Mol Biol 96: 309-316, 2005.
27. Nishiyama A, Abe Y. Aldosterone and renal injury. Nippon Yakurigaku Zasshi 124: 101-109, 2004.
28. Nishiyama A, Kobori H, Fukui T, Zhang GX, Yao L, Rahman M, Hitomi H, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension 42: 754-760, 2003.
29. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 24: 841-848, 2004.
30. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. J Clin Invest 86: 453-462, 1990.
31. Opferman JT, Korsmeyer SJ. Apoptosis in the development and maintenance of the immune system. Nat Immun 4: 410-415, 2003.
32. Pérez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, Bonventre JV, Gamba G, Bobadilla NA. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 292: F131-F139, 2007.
33. Pesce CM, Striker U, Peter E, Elliot S, Striker GE. Glomerulosclerosis at both early and late stage is associated with cell turnover in mice transgenic for growth hormone. Lab Invest 65: 601-605, 1991.
34. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105: 2212-2216, 2002.
35. Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232-237, 1999.
36. Rousseau MF, Gurné O, Duprez D, Van Mieghem W, Robert A, Ahn S, Galanti L, Ketelslegers JM. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 40: 1596-601, 2002.
37. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 31: 451-458, 2003.
38. Shimizu A, Kitamura H, Masuda Y, Ishizaki M, Sugisaki Y, Yamanaka N. Apoptosis in the repair process of experimental proliferative glomerulonephritis. Kidney Int 47: 114-121, 1995.
39. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399: 483-487, 1999.
40. Singhal PC, Bhaskaran M, Patel J, Patel K, Kasinath BS, Duraisamy S, Frank N, Reddy K, Kapasi AA. Role of P38 Mitogen-activated protein kinase phosphorylation and Fas-FasL interaction in morphine-induced macrophage apoptosis. J Immunol 168: 4025-4033, 2002.
41. Singhal PC, Sharma P, Kapasi A, Reddy K, Franki N, Gibbons N. Morphine enhances macrophage apoptosis. J Immunol 160: 1886-1893, 1998.
42. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 273: 4883-4891, 1998.
43. Soto H, Mosquera J, Rodriguez-Iturbe B, Henriquez La Roche C, Pinto A. Apoptosis in proliferative glomerulonepritis: decreased apoptosis expression in lupus nephritis. Nephrol Dial Transplant 12: 273-280, 1997.
44. Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota Z. Apoptosis in glomerular sclerosis. Kidney Int 49: 103-111, 1996.
45. Tashiro K, Kodara S, Takahashi Y, Horikoshi S, Shirato I, Tomino Y. Detection of apoptotic cells in glomeruli of patients with IgA nephropathy. Nephron 79: 21-27, 1998.
46. Terada Y, Kobayashi T, Kuwana H, Tanaka H, Inoshita S, Kuwahara M, Sasaki S. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase cyclin D1, and cyclin A. J Am Soc Nephrol 16: 2296-2305, 2005.
47. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40: 504-510, 2002.
48. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 284: 339-343, 1999.
49. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41: 1021-1026, 2003.
50. Yamamoto T, Noble NA, Miller DE, Border WA. Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int 45: 916-927, 1994.
51. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-X(L). Cell 87: 619-628, 1996.
52. Zhang W, Khanna P, Chan LL, Campbell G, Ansari NH. Diabetes-induced apoptosis in rat kidney. Biochem Mol Med 61: 58-62, 1997.